Swiss perspectives in 10 languages

Novartis buys US biotech firm Protez

Novartis has bought US-based Protez Pharmaceuticals in a deal worth up to $400 million, giving it the rights to an antibiotic that could be used to fight superbugs such as MRSA.

The Swiss drug maker will initially pay $100 million for privately held Protez, with a potential for up to $300 million of additional payments depending on the success of the antibiotic PZ-601.

The emergence of superbugs such as MRSA, which are resistant to existing medicines, has increased the need for alternative treatments and refocused attention on antibiotics.

“The acquisition of Protez Pharmaceuticals provides rights to PZ-601 and further strengthens the speciality medicines development portfolio in hospital infections,” Novartis said in a statement.

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

SWI - a branch of Swiss Broadcasting Corporation SRG SSR

SWI - a branch of Swiss Broadcasting Corporation SRG SSR